Company: EDSA
Filing Date: 2025-12-12
Form Type: 10-K
Source: 0001171843-25-007914
Chunk: 475

Company: Edesa Biotech, Inc.
Filing Date: 2025-12-12
Form: 10-K
Item: Item 1B
Chunk 475
---
,389)

			54,515,421

			47,236,024

			Authorized preferred shares issued and outstanding

			150 Series A-1 preferred shares (September 30, 2024 - 0)

			1,092,133

			-

			834 Series B-1 preferred shares (September 30, 2024 - 0)

			8,168,063

			-

			Additional paid-in capital

			14,753,110

			13,576,757

			Accumulated other comprehensive loss

			(165,771
			)

			(242,613
			)

			Accumulated deficit

			(65,910,974
			)

			(58,589,013
			)

			Total shareholders' equity

			12,451,982

			1,981,155

			Total liabilities and shareholders' equity

			$
			13,530,518

			$
			3,813,982

The accompanying notes are an integral part of these consolidated financial statements.

F-4

EDESA BIOTECH, INC.

Consolidated Statements of Operations and Comprehensive Loss

			Fiscal Year End 

			September 30, 2025

			September 30, 2024

			Expenses:

			Research and development

			$
			3,668,738

			$
			2,881,967

			General and administrative

			4,242,828

			4,132,777

			Loss from operations

			(7,911,566
			)

			(7,014,744
			)

			Other income :

			Reimbursement grant income

			783,894

			698,277

			Interest income

			2,558

			153,498

			Misc other income

			-

			14,766

			Foreign exchange (loss)

			(59,609
			)

			(21,042
			)

			726,843

			845,499

			Loss before income taxes

			(7,184,723
			)

			(6,169,245
			)

			Income tax expense

			800